“Management’s relentless efforts to increase overall portfolio value not only involves adding new companies annually and growing its Trendlines Labs, but also expansion into other geographical markets. Trendlines recently set up its first overseas subsidiary in Singapore (76.4%-owned Trendlines Medical Singapore), which adopts a similar investment model, and has clinched a partnership with Singapore General Hospital (SGH) to develop and conduct clinical trials,” say Ngoh and Tng.
SINGAPORE (May 23): CIMB Research has issued an unrated report on Trendlines Group as an “intensely hands-on technology” incubator based in Israel, and as a stock that is currently trading at a discount to its global peers.
In a Tuesday note, analysts Ngoh Yi Sin and William Tng highlight the incubator’s experienced management team and strong financial backing from Israel’s government, with the group further seeking to add another 8-10 companies to its existing portfolio of 46.
